DiabetesMine Innovation Summit Advisory Board

We’d like to thank our Summit Advisory Board members:

Adam Brown is currently the Chief of Staff at Close Concerns and the Co-Managing Editor of diaTribe (www.diaTribe.org). He graduated summa cum laude from the Wharton School of the University of Pennsylvania in 2011 pursuing concentrations in marketing and health care management & policy. Adam was a Joseph Wharton and Benjamin Franklin Scholar and completed his senior thesis on the motivational and financial factors associated with optimal diabetes control. He was diagnosed with type 1 diabetes at the age of 12 and has worn an insulin pump for the last eleven years and a CGM for the past three years. Much of Adam’s writing for Close Concerns and diaTribe focuses on diabetes technology, especially CGM, insulin pumps, and the artificial pancreas. Adam is on the board of directors of Insulindependence and the SF branch of JDRF. He is passionate about cycling, strength training, nutrition, and wellness and spends his free time outdoors and staying active.

Bruce Buckingham, M.D. is a Professor of Pediatric Endocrinology at Stanford University and Packard Children’s Hospital. Dr. Buckingham’s research interests have focused on continuous glucose monitoring in children and “closing- the-loop”. These efforts are being funded by the JDRF, NIH and the Helmsley Foundation and are currently focused on preventing nocturnal hypoglycemia with a predictive low-glucose suspend system, and full overnight closed-loop. Other closed-loop studies are focused on 24/7 closed loop in the ambulatory setting and assessing ways to improve insulin infusion sets to prolong their wear.

No.323 - Cleanse Sebum

Larry Chu is a practicing physician who runs the Anesthesia Informatics and Media (AIM) lab at Stanford University. He is an Associate Professor of Anesthesia on the faculty of the Stanford University School of Medicine.

He is the Executive Director of Stanford Medicine X, a conference that aims to explore how emerging technologies will advance the practice of medicine, improve health, and empower patients to be active participants in their own care. When not organizing conferences, Dr. Chu studies how information technologies can be used to improve medical education and collaborates with researchers in simulation and computer science at Stanford to study how cognitive aids can improve health care outcomes. Dr. Chu also has an NIH-funded clinical research laboratory where he studies opioid analgesic tolerance and physical dependence.

Kelly’s passion for the field comes from her extensive professional work as well as her personal experience as a patient with type 1 diabetes for nearly 25 years. Her analytic expertise comes from nearly 10 years researching medical technology and pharma as an equity research analyst. Prior to starting Close Concerns, Kelly worked in the financial sector, writing about medical technology companies, and at McKinsey & Company, where a majority of her work focused in the healthcare practice. Kelly is widely viewed as an expert on diabetes and obesity markets and as a frequent speaker on the public health implications of diabetes and obesity, she is a tireless supporter of patients. A longtime diabetes advocate, Kelly is on the board of directors of the Diabetes Hands Foundation and the Behavioral Diabetes Institute and was previously on the Executive Board of the SF Bay Area JDRF. Kelly is a graduate of Amherst College and Harvard Business School. She lives in San Francisco with her husband and three children.

Manny Hernandez was diagnosed with diabetes in 2002. In 2007, Manny and Andreina Davila, his wife, established two online communities for people touched by diabetes: TuDiabetes.org (in English) and EsTuDiabetes (in Spanish). A year later they co-founded the Diabetes Hands Foundation, a 501(c)3 nonprofit that connects, empowers, and mobilizes the diabetes community. Manny served as of the President of the Diabetes Hands Foundation until early 2015, when he joined consumer digital health company Livongo Health as Senior Vice President, Member Experience.

Dr. Jackson is an Investigator in the Section on Immunobiology, a Senior Physician and the Director of the Hood Center for the Prevention of Childhood Diabetes at Joslin, and an Assistant Professor of Medicine at Harvard Medical School. He received his medical degree from Ohio State University School of Medicine and completed residency training at Worcester Memorial Hospital as well as fellowship training in Endocrinology at Duke. He is a former Mary K. Iacocca Fellow and recipient of the Cookie Pierce Research Award from the Juvenile Diabetes Research Foundation.

No.203 - Prevent Elasticity Damage

Through the 1980s and 1990s, Dr. Jackson and his collaborators broke new ground in the use of markers called autoantibodies as powerful tools for risk assessment. His efforts led to the launch of the Diabetes Prevention Trial – Type 1 (DPT-1), the first National Institutes of Health-sponsored clinical study of the effectiveness of preventive strategies in first- and second-degree relatives of patients with type 1 diabetes. In addition to these programs based in underserved areas, Dr. Jackson launched an in-house Diabetes Outpatient Intensive Treatment (DO IT) program. This three-and-a-half-day program—offered at Joslin Clinic by Dr. Jackson and a team of diabetes educators, dietitians, exercise physiologists and social workers—consists of a thorough set of physical assessments and educational workshops aimed at providing patients with up-to- date, personalized information on how well they are controlling their diabetes and what steps they can take to control it better. Randomized controlled studies have shown the effectiveness of this program, and it continues as a testing area for new approaches to diabetes care.

Entrepreneur and patient advocate Anna McCollister-Slipp is co-founder of Galileo Analytics, a Visual Data Exploration and advanced data analytics company focused on democratizing access to and understanding of complex health data.Anna’s passion for innovation in health data analytics is rooted in her personal experiences living with type 1 diabetes. In her professional and personal activities, Anna seeks to build platforms for better understanding of and engagement with the needs of patients. She speaks frequently about the promise of digital health and medical devices for empowering and engaging consumers and patients with chronic disease, urging device manufacturers and policymakers to prioritize human factors design, adopt standardized data formats and enable device and data interoperability. As a health IT entrepreneur and patient advocate, Anna has been appointed to and served on a number of government and private committees and boards aimed at promoting innovative ways to better understand, manage and treat complex chronic health conditions, such as diabetes. She was a member of the the ONC HIT Policy Committee’s FDASIA Workgroup, charged with advising the government on a regulatory pathway for HIT that would protect patients and promote innovation.Anna’s work as an advocate and entrepreneur has been featured in an array of publications and online media. She was named by XX In Health as a “Woman to Watch” at Health Datapalooza 2013, and as co-founder of Galileo Analytics, was one of a select group of innovators invited to participate in “The Hive” at TEDMED 2013.

Cynthia Rice is Senior Vice President for Advocacy and Policy for JDRF. She is responsible for JDRF’s advocacy to Congress, the executive branch, regulatory agencies, and health plans to accelerate therapies to cure, treat, and prevent type 1 diabetes. JDRF is the leading global organization funding type 1 diabetes research. Driven by passionate, grassroots volunteers connected to children, adolescents, and adults with the disease, JDRF’s goal is to progressively remove the impact of T1D from people’s lives until we achieve a world without T1D.

Cynthia joined JDRF, then known as the Juvenile Diabetes Research Foundation, in 2005 and led a cross-departmental staff team that developed the Artificial Pancreas Project. She was promoted to Vice President, Government Relations in 2009 and to her current role in 2013.

She has extensive experience leading complex advocacy projects in both the government and nonprofit sectors. In the White House from 1997 to 2000, she served as a Special Assistant to the President for Domestic Policy, coordinating numerous high profile policy initiatives involving experts from multiple agencies and employing various legislative, regulatory, and communications tactics.

Prior to joining the White House, she served in the mid-1990s in the U.S. Senate as a Legislative Assistant to two senior members of the Finance Committee, Senator Daniel Patrick Moynihan and Senator John B. Breaux. In those capacities she helped advance and amend a variety of budget, health, and domestic policy legislation. From 2001-2005, Cynthia served as Vice President for Policy at the New Democrat Network, where she led efforts to promote the group’s policy agenda to elected officials and the public.

Cynthia has a Master’s in Public Policy from the University of California at Berkeley, and a bachelor’s degree from Harvard University.

Read more on: diabetesmine